The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in
treating patients with Sjogren's syndrome (SS). Rituximab is a laboratory-made antibody
currently used to treat some kinds of lymphoma. Rituximab may also help people with SS, a
disease of the immune system. However, the safety of rituximab in SS patients must first be
established.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)